Want to see HIMS full AI Analyst Report?
HIMS Stock Chart & Stats
$29.83
$1.42(5.06%)
At close: 4:00 PM EDT
$29.83
$1.42(5.06%)
Day’s Range― - ―
52-Week Range$13.74 - $57.45
Previous CloseN/A
Volume4.79M
Average Volume (3M)9.82M
Market Cap
$6.55B
Enterprise Value$8.74B
Total Cash (Recent Filing)$841.05M
Total Debt (Recent Filing)$1.55B
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Nov 09, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding224,935,790
10 Day Avg. Volume11,042,292
30 Day Avg. Volume9,823,679
Financial Highlights & Ratios
PEG Ratio-33.04
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue3.39
Enterprise Value/Gross Profit5.24
Enterprise Value/Ebitda-114.37
Forecast
1Y Price Target
$32.82Price Target Upside10.02% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$3.21B
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Subscriber GrowthRapid revenue growth combined with a nearly three-million subscriber base indicates expanding customer adoption and a larger platform for cross-selling. Continued additions across specialties and geographies can reinforce scale, support recurring demand, and improve the company’s ability to compound revenue over the next several quarters.
Positive Cash GenerationPositive operating and free cash flow provide an important foundation for funding operations and growth without relying entirely on external capital. Generating cash despite a TTM accounting loss suggests the platform retains underlying cash-producing capacity, although conversion should be monitored as the business expands.
AI Efficiency And Engagement PotentialEarly AI results point to a scalable improvement in both customer engagement and service efficiency. Higher interaction levels may strengthen the care experience, while reduced nonclinical workload can lower the cost to serve; management expects the investments to pay back within 12–18 months.
Bears Say
Sharp Increase In LeverageThe sharp rise in debt relative to equity materially reduces financial flexibility and increases the consequences of inconsistent profitability. Higher leverage can constrain capital allocation, make growth more dependent on financing capacity, and leave less balance-sheet room to absorb operating setbacks over the next several quarters.
Persistent Gross-Margin PressureMargin compression is tied to the strategic shift toward branded weight-loss products and international revenue, which management expects to keep gross margins below historical levels. If this mix persists, the company may need stronger revenue scale or operating efficiencies to protect EBITDA and cash generation.
Regulatory And Legal UncertaintyThe FTC complaint creates an ongoing legal and regulatory overhang that could generate additional costs, management distraction, or changes to operating practices. The uncertainty is particularly relevant to a digitally delivered healthcare model because regulatory outcomes may affect how products and services are marketed or provided.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was $13.74 and its highest was $57.45 in the past 12 months.
What is Hims & Hers Health’s market cap?
Hims & Hers Health’s market cap is $6.55B.
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is Nov 09, 2026 which is in 21 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Aug 10, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.32.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is 0.06.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 224,935,790 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -3.966%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Currently, no hedge funds are holding shares in HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.82 (10.02% Upside)
$32.82 (10.02% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 72%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 81.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.54%
12-Months-Change
Fundamentals
Return on Equity
-30.03%
Trailing 12-Months
Asset Growth
93.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hims & Hers Health
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
HIMS Company Deck
HIMS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and growth-oriented outlook: strong revenue and subscriber growth, raised guidance, meaningful international scale from the Eucalyptus acquisition, and promising AI-driven engagement and efficiency gains. These positives are tempered by margin compression from mix shift toward branded weight loss and international sales, a GAAP loss driven by one-time costs, short-term negative cash flow in the quarter, and regulatory/legal uncertainties (FTC action and dependence on FDA rulemaking for peptides). Management highlighted liquidity actions and expects AI investments to pay back within 12–18 months, signaling confidence in the path to improved profitability.View all HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$32.82
▲(10.02% Upside)
Technical Analysis
Acadia Healthcare
―
biote
―
Lifestance Health Group
―
EUDA Health Holdings
―
Mobile-health Network Solutions Class A
―
Ownership Overview
4.81% Insiders
14.65% Mutual Funds
0.10% Other Institutional Investors
59.20% Public Companies and Individual Investors